Nanoformulations of Rilpivirine for Topical Pericoital and Systemic Coitus-Independent Administration Efficiently Prevent HIV Transmission

Martina Kovarova, Olivia D. Council, Abhijit A. Date, Julie M. Long, Tomonori Nochii, Michael A. Belshan, Annemarie Shibata, Heather Vincent, Caroline E. Baker, William O. Thayer, Guenter Kraus, Sophie Lachaud-Durand, Peter Williams, Christopher J. Destache, J. Victor Garcia

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Vaginal HIV transmission accounts for the majority of new infections worldwide. Currently, multiple efforts to prevent HIV transmission are based on pre-exposure prophylaxis with various antiretroviral drugs. Here, we describe two novel nanoformulations of the reverse transcriptase inhibitor rilpivirine for pericoital and coitus-independent HIV prevention. Topically applied rilpivirine, encapsulated in PLGA nanoparticles, was delivered in a thermosensitive gel, which becomes solid at body temperature. PLGA nanoparticles with encapsulated rilpivirine coated the reproductive tract and offered significant protection to BLT humanized mice from a vaginal high-dose HIV-1 challenge. A different nanosuspension of crystalline rilpivirine (RPV LA), administered intramuscularly, protected BLT mice from a single vaginal high-dose HIV-1 challenge one week after drug administration. Using transmitted/founder viruses, which were previously shown to establish de novo infection in humans, we demonstrated that RPV LA offers significant protection from two consecutive high-dose HIV-1 challenges one and four weeks after drug administration. In this experiment, we also showed that, in certain cases, even in the presence of drug, HIV infection could occur without overt or detectable systemic replication until levels of drug were reduced. We also showed that infection in the presence of drug can result in acquisition of multiple viruses after subsequent exposures. These observations have important implications for the implementation of long-acting antiretroviral formulations for HIV prevention. They provide first evidence that occult infections can occur, despite the presence of sustained levels of antiretroviral drugs. Together, our results demonstrate that topically- or systemically administered rilpivirine offers significant coitus-dependent or coitus-independent protection from HIV infection.

Original languageEnglish
Article numbere1005075
JournalPLoS Pathogens
Volume11
Issue number8
DOIs
StatePublished - Aug 1 2015

Fingerprint

Rilpivirine
Coitus
HIV
Pharmaceutical Preparations
HIV-1
Infection
Nanoparticles
HIV Infections
Viruses
Reverse Transcriptase Inhibitors
Body Temperature

All Science Journal Classification (ASJC) codes

  • Microbiology
  • Parasitology
  • Virology
  • Immunology
  • Genetics
  • Molecular Biology

Cite this

Nanoformulations of Rilpivirine for Topical Pericoital and Systemic Coitus-Independent Administration Efficiently Prevent HIV Transmission. / Kovarova, Martina; Council, Olivia D.; Date, Abhijit A.; Long, Julie M.; Nochii, Tomonori; Belshan, Michael A.; Shibata, Annemarie; Vincent, Heather; Baker, Caroline E.; Thayer, William O.; Kraus, Guenter; Lachaud-Durand, Sophie; Williams, Peter; Destache, Christopher J.; Garcia, J. Victor.

In: PLoS Pathogens, Vol. 11, No. 8, e1005075, 01.08.2015.

Research output: Contribution to journalArticle

Kovarova, M, Council, OD, Date, AA, Long, JM, Nochii, T, Belshan, MA, Shibata, A, Vincent, H, Baker, CE, Thayer, WO, Kraus, G, Lachaud-Durand, S, Williams, P, Destache, CJ & Garcia, JV 2015, 'Nanoformulations of Rilpivirine for Topical Pericoital and Systemic Coitus-Independent Administration Efficiently Prevent HIV Transmission', PLoS Pathogens, vol. 11, no. 8, e1005075. https://doi.org/10.1371/journal.ppat.1005075
Kovarova, Martina ; Council, Olivia D. ; Date, Abhijit A. ; Long, Julie M. ; Nochii, Tomonori ; Belshan, Michael A. ; Shibata, Annemarie ; Vincent, Heather ; Baker, Caroline E. ; Thayer, William O. ; Kraus, Guenter ; Lachaud-Durand, Sophie ; Williams, Peter ; Destache, Christopher J. ; Garcia, J. Victor. / Nanoformulations of Rilpivirine for Topical Pericoital and Systemic Coitus-Independent Administration Efficiently Prevent HIV Transmission. In: PLoS Pathogens. 2015 ; Vol. 11, No. 8.
@article{720e27243a7e4c8d92480260ee200d51,
title = "Nanoformulations of Rilpivirine for Topical Pericoital and Systemic Coitus-Independent Administration Efficiently Prevent HIV Transmission",
abstract = "Vaginal HIV transmission accounts for the majority of new infections worldwide. Currently, multiple efforts to prevent HIV transmission are based on pre-exposure prophylaxis with various antiretroviral drugs. Here, we describe two novel nanoformulations of the reverse transcriptase inhibitor rilpivirine for pericoital and coitus-independent HIV prevention. Topically applied rilpivirine, encapsulated in PLGA nanoparticles, was delivered in a thermosensitive gel, which becomes solid at body temperature. PLGA nanoparticles with encapsulated rilpivirine coated the reproductive tract and offered significant protection to BLT humanized mice from a vaginal high-dose HIV-1 challenge. A different nanosuspension of crystalline rilpivirine (RPV LA), administered intramuscularly, protected BLT mice from a single vaginal high-dose HIV-1 challenge one week after drug administration. Using transmitted/founder viruses, which were previously shown to establish de novo infection in humans, we demonstrated that RPV LA offers significant protection from two consecutive high-dose HIV-1 challenges one and four weeks after drug administration. In this experiment, we also showed that, in certain cases, even in the presence of drug, HIV infection could occur without overt or detectable systemic replication until levels of drug were reduced. We also showed that infection in the presence of drug can result in acquisition of multiple viruses after subsequent exposures. These observations have important implications for the implementation of long-acting antiretroviral formulations for HIV prevention. They provide first evidence that occult infections can occur, despite the presence of sustained levels of antiretroviral drugs. Together, our results demonstrate that topically- or systemically administered rilpivirine offers significant coitus-dependent or coitus-independent protection from HIV infection.",
author = "Martina Kovarova and Council, {Olivia D.} and Date, {Abhijit A.} and Long, {Julie M.} and Tomonori Nochii and Belshan, {Michael A.} and Annemarie Shibata and Heather Vincent and Baker, {Caroline E.} and Thayer, {William O.} and Guenter Kraus and Sophie Lachaud-Durand and Peter Williams and Destache, {Christopher J.} and Garcia, {J. Victor}",
year = "2015",
month = "8",
day = "1",
doi = "10.1371/journal.ppat.1005075",
language = "English",
volume = "11",
journal = "PLoS Pathogens",
issn = "1553-7366",
publisher = "Public Library of Science",
number = "8",

}

TY - JOUR

T1 - Nanoformulations of Rilpivirine for Topical Pericoital and Systemic Coitus-Independent Administration Efficiently Prevent HIV Transmission

AU - Kovarova, Martina

AU - Council, Olivia D.

AU - Date, Abhijit A.

AU - Long, Julie M.

AU - Nochii, Tomonori

AU - Belshan, Michael A.

AU - Shibata, Annemarie

AU - Vincent, Heather

AU - Baker, Caroline E.

AU - Thayer, William O.

AU - Kraus, Guenter

AU - Lachaud-Durand, Sophie

AU - Williams, Peter

AU - Destache, Christopher J.

AU - Garcia, J. Victor

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Vaginal HIV transmission accounts for the majority of new infections worldwide. Currently, multiple efforts to prevent HIV transmission are based on pre-exposure prophylaxis with various antiretroviral drugs. Here, we describe two novel nanoformulations of the reverse transcriptase inhibitor rilpivirine for pericoital and coitus-independent HIV prevention. Topically applied rilpivirine, encapsulated in PLGA nanoparticles, was delivered in a thermosensitive gel, which becomes solid at body temperature. PLGA nanoparticles with encapsulated rilpivirine coated the reproductive tract and offered significant protection to BLT humanized mice from a vaginal high-dose HIV-1 challenge. A different nanosuspension of crystalline rilpivirine (RPV LA), administered intramuscularly, protected BLT mice from a single vaginal high-dose HIV-1 challenge one week after drug administration. Using transmitted/founder viruses, which were previously shown to establish de novo infection in humans, we demonstrated that RPV LA offers significant protection from two consecutive high-dose HIV-1 challenges one and four weeks after drug administration. In this experiment, we also showed that, in certain cases, even in the presence of drug, HIV infection could occur without overt or detectable systemic replication until levels of drug were reduced. We also showed that infection in the presence of drug can result in acquisition of multiple viruses after subsequent exposures. These observations have important implications for the implementation of long-acting antiretroviral formulations for HIV prevention. They provide first evidence that occult infections can occur, despite the presence of sustained levels of antiretroviral drugs. Together, our results demonstrate that topically- or systemically administered rilpivirine offers significant coitus-dependent or coitus-independent protection from HIV infection.

AB - Vaginal HIV transmission accounts for the majority of new infections worldwide. Currently, multiple efforts to prevent HIV transmission are based on pre-exposure prophylaxis with various antiretroviral drugs. Here, we describe two novel nanoformulations of the reverse transcriptase inhibitor rilpivirine for pericoital and coitus-independent HIV prevention. Topically applied rilpivirine, encapsulated in PLGA nanoparticles, was delivered in a thermosensitive gel, which becomes solid at body temperature. PLGA nanoparticles with encapsulated rilpivirine coated the reproductive tract and offered significant protection to BLT humanized mice from a vaginal high-dose HIV-1 challenge. A different nanosuspension of crystalline rilpivirine (RPV LA), administered intramuscularly, protected BLT mice from a single vaginal high-dose HIV-1 challenge one week after drug administration. Using transmitted/founder viruses, which were previously shown to establish de novo infection in humans, we demonstrated that RPV LA offers significant protection from two consecutive high-dose HIV-1 challenges one and four weeks after drug administration. In this experiment, we also showed that, in certain cases, even in the presence of drug, HIV infection could occur without overt or detectable systemic replication until levels of drug were reduced. We also showed that infection in the presence of drug can result in acquisition of multiple viruses after subsequent exposures. These observations have important implications for the implementation of long-acting antiretroviral formulations for HIV prevention. They provide first evidence that occult infections can occur, despite the presence of sustained levels of antiretroviral drugs. Together, our results demonstrate that topically- or systemically administered rilpivirine offers significant coitus-dependent or coitus-independent protection from HIV infection.

UR - http://www.scopus.com/inward/record.url?scp=84940731025&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940731025&partnerID=8YFLogxK

U2 - 10.1371/journal.ppat.1005075

DO - 10.1371/journal.ppat.1005075

M3 - Article

VL - 11

JO - PLoS Pathogens

JF - PLoS Pathogens

SN - 1553-7366

IS - 8

M1 - e1005075

ER -